Stay updated on FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.

Latest updates to the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page shows Revision: v3.4.2, replacing the previous Revision: v3.4.1. This is a minor metadata update to the page version.SummaryDifference0.0%

- Check20 days agoChange DetectedMinor page update: Revision from v3.4.0 to v3.4.1 with no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedUI changes include showing the glossary option and minor label/versioning updates (e.g., Last Update Submitted that Met QC Criteria vs met QC Criteria; No FEAR Act data vs data) on the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a dedicated Locations section with site entries in Georgia, New York, Texas, Washington, and Ontario, and updated the page revision to v3.3.3. Removed the older HHS Vulnerability Disclosure link and the prior location sections tied to revision v3.3.2.SummaryDifference0.4%

- Check92 days agoChange DetectedAdded a note that PubMed publications are automatically filled in from PubMed and updated the page revision to v3.3.2 (replacing v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.